MED

Medifast, Inc. (MED) 10Y Growth Potential Analysis (2026)

Invetso Score: 4.8/10 — Balanced · Last Updated: 2026-09-01

Overall Score

Growth Runway

Revenue base is still small at a $140.9M market cap, which leaves room for expansion if execution improves.

Gross margin remains healthy at 69.2%, but operating margin is still negative at -5.5%, limiting near-term compounding.

Profitability

TTM returns remain negative, including ROE of -12.7% and ROIC of -7.7%, indicating the business is not yet generating durable economic profits.

EBITDA margin is slightly negative at -1.1% and net margin is -8.1%, showing profitability remains under pressure despite strong gross margin.

Financial Strength

Liquidity is strong with a current ratio of 4.86 and quick ratio of 4.35, giving the company flexibility to fund operations.

Leverage appears manageable with debt-to-equity of 0.14 and debt-to-assets of 0.11, though solvency metrics remain weak due to negative earnings.

Cash Generation

Operating cash flow is positive, but free cash flow conversion is modest with FCF yield at 2.8% and price-to-FCF at 35.1x.

Cash conversion is supported by favorable working-capital dynamics, including a cash conversion cycle of -57.0 days.

Valuation

The stock screens inexpensive on sales and book value, with EV/sales at 0.30x and price/book at 0.72x.

However, valuation is less compelling on cash flow, with price-to-operating-cash-flow at 16.0x and price-to-free-cash-flow at 35.1x.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Medifast, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →